



Budget 2024-25

This information is accurate as of 14 May 2024.

Pharmaceutical Benefits Scheme new and amended listings

The Pharmaceutical Benefits Scheme (PBS) provides subsidised access to medicines to Australian residents and overseas visitors from countries under Reciprocal Health Care Agreements.

This measure lists new medicines on the PBS and expands access to others. It will provide better treatment and improved health for Australians.

New and amended listings from 1 January 2024

- Lumacaftor and ivacaftor (Orkambi®) for the treatment of cystic fibrosis (extended to include patients from age 1).
- Olaparib (Lynparza®) for the treatment of high-grade stage III/IV epithelial ovarian, fallopian tube or primary peritoneal cancer (homologous recombination deficiency (HRD) positive breast cancer gene (BRCA) wild type).
- Ravulizumab (Ultomiris®) for the treatment of atypical haemolytic uraemic syndrome (aHUS).
- Ustekinumab (Stelara®) for the treatment of fistulising Crohn's disease.

New and amended listings from 1 February 2024

- Tebentafusp (Kimmtrak®) for the treatment of advanced (unresectable or metastatic) uveal melanoma.
- Natalizumab (Tysabri®) for the treatment of clinically definite relapsing-remitting multiple sclerosis (RRMS).
- Relatlimab and nivolumab (Opdualag®) for the treatment of unresectable stage III or stage IV malignant melanoma.

New and amended listings from 1 March 2024

- Abiraterone and methylprednisolone (Yonsa MPRED®) for the treatment of metastatic castration sensitive carcinoma of the prostate.
- Dapagliflozin (Forxiga®) for the treatment of chronic heart failure with a left ventricular ejection fraction greater than 40%.
- Nusinersen (Spinraza®) for the treatment of pre-symptomatic spinal muscular atrophy (SMA) with a SMN2 gene copy number of 3.

New and amended listings from 1 April 2024

- Empagliflozin (Jardiance®) for the treatment of chronic kidney disease.
- Inclisiran (Leqvio®) for the treatment of hypercholesterolaemia.

- Methotrexate (Trexject) for the treatment of juvenile idiopathic arthritis (JIA).

New and amended listings from 1 May 2024

- Tafamidis (Vyndamax®) for the treatment of transthyretin amyloid cardiomyopathy.
- Difelikefalin (Korsuva®) for the treatment of moderate to severe pruritus (itching) associated with chronic kidney disease.
- Mavacamten (Camzyos®) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
- Eltrombopag (Revolade®) for the treatment of severe aplastic anaemia.
- Abemaciclib (Verzenio®) for the treatment of hormone receptor (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer.
- Dostarlimab (Jemperli®) for the treatment of advanced, metastatic or recurrent endometrial cancer.

Services Australia will get \$0.6 million in 2023–24, and \$0.8 million over 4 years through to 2027–28.

The PBS is managed by the Department of Health and Aged Care and administered by Services Australia.

This measure isn't subject to legislation passing.

Who does this measure affect?

This affects Australian residents and overseas visitors from countries under Reciprocal Health Care Agreements.

When will this start and finish?

The new and amended PBS listings are effective from dates stated above and are ongoing.